Hanmi’s P3T for ’Korean GLP-1 obesity drug’ is approved
By Lee, Seok-Jun | translator Kim, Jung-Ju
23.10.23 18:34:17
가나다라
0
MFDS approves Phase III trial for ‘efpeglenatide’ in Korea
Clinical development to start at full scale at the end of the month… to commercialize the drug within 3 years
The development of an ‘GLP-1 obesity treatment optimized for Koreans' is gaining momentum.
Hanmi Pharmaceutical announced on the 23rd that the Ministry of Food and Drug Safety approved the Phase III clinical trial for its ‘efpeglenatide,’ a glucagon-like peptide 1 (GLP-1) receptor agonist developed by the company.
Epeglenatide is a GLP-1 receptor agonist that acts as a GLP-1 hormone analogue that helps secrete insulin and suppress appetite in the body. After being licensed out to the global pharmaceutical company Sanofi in 2015, its efficacy in weight loss and blood sugar control was confirmed through a large-scale global Phase III clinical trial.
In addition, it
Lee, Seok-Jun(wiviwivi@dailypharm.com)
If you want to see the full article, please JOIN US (click)